PODD Stock Analysis: Insulet | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 10.578m USD | 12M Return: -60.4% | US45784P1012 | Charts, Fundamentals & Technical Analysis

Pumps, Diabetes Management, Automated Delivery, Pharmaceutical Pods
Total Rating 52
Safety 69
Buy Signal 0.07
Health Care Equipment
Sub-Industry Rotation: -2.2
Market Cap: 10.6B
Avg Turnover: 200M
Risk 3d forecast
Volatility42.8%
VaR 5th Pctl7.07%
VaR vs Median0.51%
Reward TTM
Sharpe Ratio-1.85
Rel. Str. IBD9.2
Rel. Str. Peer Group10.4 pctl
Character TTM
Beta0.192
Beta Downside0.644
Hurst Exponent0.384
Choppyness65.9%
Drawdowns 3y
Max DD63.02%
CAGR/Max DD-0.16
CAGR/Mean DD-0.48
EPS (Earnings per Share) EPS (Earnings per Share) of PODD over the last years for every Quarter: "2021-09": 0.2, "2021-12": 0.42, "2022-03": 0.4, "2022-06": -0.08, "2022-09": 0.41, "2022-12": 0.24, "2023-03": 0.23, "2023-06": 0.38, "2023-09": 0.71, "2023-12": 1.4, "2024-03": 0.73, "2024-06": 0.55, "2024-09": 0.9, "2024-12": 1.15, "2025-03": 1.02, "2025-06": 1.17, "2025-09": 1.24, "2025-12": 1.55, "2026-03": 1.42, "2026-06": 1.66, "2026-09": 1.99,
EPS CAGR: 34.49%
EPS Trend: 97.7%
Last SUE: 4.00
Qual. Beats: 3
Revenue Revenue of PODD over the last years for every Quarter: 2021-09: 275.6, 2021-12: 307.7, 2022-03: 295.4, 2022-06: 299.4, 2022-09: 340.8, 2022-12: 369.7, 2023-03: 358.1, 2023-06: 396.5, 2023-09: 432.7, 2023-12: 509.8, 2024-03: 441.7, 2024-06: 488.5, 2024-09: 543.9, 2024-12: 597.5, 2025-03: 569, 2025-06: 649.1, 2025-09: 706.3, 2025-12: 783.8, 2026-03: 761.7, 2026-06: 801.7, 2026-09: 842,
Rev. CAGR: 26.97%
Rev. Trend: 99.8%
Last SUE: 1.18
Qual. Beats: 13

Warnings

Below Avwap Earnings
Below Sma 200d

Tailwinds

Pead
Garp
Confidence

Seasonality 11.9 years of data, until 10/2026

Jan +0.4% 0
Feb -1.4% 4
Mar +0.1% 0
Apr -1.9% 28
May -8.5% 28
Jun +2.9% 28
Jul +0.4% 0
Aug +4.4% 28
Sep -4.7% 14
Oct +1.0% 0
Nov +13.1% 21
Dec -3.8% 21

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: PODD Insulet

Insulet Corporation (NASDAQ: PODD) is a U.S.-based mid-cap health care equipment company that develops, manufactures, and sells insulin delivery systems primarily for people with insulin-dependent diabetes. Its core product family is the Omnipod platform, a line of tubeless, wearable insulin pumps that include the Omnipod 5 automated insulin delivery system (integrated with third-party continuous glucose monitors via Bluetooth), the Omnipod DASH system (smartphone-controlled), and the legacy Omnipod Insulin Management System.

The company also supplies pods to Amgen for use in the Neulasta Onpro kit, a drug delivery system designed to reduce infection risk following intensive chemotherapy. Insulet sells its diabetes products directly to end-users through the pharmacy channel and via independent distributors, with operations spanning the United States and international markets. Insulet was incorporated in 2000 and is headquartered in Acton Massachusetts.

Headlines to Watch Out For
  • Omnipod 5 adoption drives U.S. type 2 diabetes expansion
  • Tubeless pump competition intensifies versus Medtronic and Tandem
  • Gross margins expand as automated manufacturing scales globally
Piotroski VR-10 (Strict) 7.5
Net Income: 428.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA -6.29 > 1.0
NWC/Revenue: 38.48% < 20% (prev 48.05%; Δ -9.57% < -1%)
CFO/TA 0.15 > 3% & CFO 509.0m > Net Income 428.8m
Net Debt (382.3m) to EBITDA (718.6m): 0.53 < 3
Current Ratio: 2.51 > 1.5 & < 3
Outstanding Shares: last quarter (69.5m) vs 12m ago -1.65% < -2%
Gross Margin: 71.88% > 18% (prev 71.46%; Δ 0.42% > 0.5%)
Asset Turnover: 98.98% > 50% (prev 83.25%; Δ 15.73% > 0%)
Interest Coverage Ratio: 10.24 > 6 (EBIT TTM 613.1m / Interest Expense TTM 59.9m)
Altman Z'' 5.13
A: 0.36 (Total Current Assets 2.04b - Total Current Liabilities 814.4m) / Total Assets 3.42b
B: 0.18 (Retained Earnings 614.5m / Total Assets 3.42b)
C: 0.19 (EBIT TTM 613.1m / Avg Total Assets 3.22b)
D: 0.86 (Book Value of Equity 1.58b / Total Liabilities 1.84b)
Altman-Z'' = 5.13 = AAA
Beneish M -2.75
DSRI: 1.18 (Receivables 689.0m/462.2m, Revenue 3.19b/2.52b)
GMI: 0.99 (GM 71.46% / 71.88%)
AQI: 0.91 (AQ_t 0.13 / AQ_t-1 0.15)
SGI: 1.26 (Revenue 3.19b / 2.52b)
TATA: -0.02 (NI 428.8m - CFO 509.0m) / TA 3.42b)
Beneish M = -2.75 (Cap -4..+1) = A
What is the price of PODD shares?

As of November 20, 2026, the stock is trading at USD 137.23 with a total of 1,553,033 shares traded. Over the past week, the price has changed by -8.08%, over one month by -3.33%, over three months by -9.43% and over the past year by -60.38%.

Current recommended Stop Loss: 124.60 (which is 9.2% or 1.9 ATR below the current price).

Is PODD a buy, sell or hold?

Insulet has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PODD.

  • StrongBuy: 11
  • Buy: 4
  • Hold: 11
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PODD price?
Analysts Target Price 178.6 30.1%
Insulet (PODD) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 10.6b (10.6b USD * 1.0 USD.USD)
P/E Trailing = 24.915
P/E Forward = 19.7628
P/S = 3.3167
P/B = 6.6986
P/EG = 1.1898
Revenue TTM = 3.19b USD
EBIT TTM = 613.1m USD
EBITDA TTM = 718.6m USD
Long Term Debt = 943.0m USD (from longTermDebt, last quarter)
Short Term Debt = 19.1m USD (from shortTermDebt, last quarter)
Debt = 966.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.60m
Net Debt = 382.3m USD (calculated: Debt 966.7m - CCE 584.4m)
Enterprise Value = 11.0b USD (10.6b + Debt 966.7m - CCE 584.4m)
Interest Coverage Ratio = 10.24 (Ebit TTM 613.1m / Interest Expense TTM 59.9m)
EV/FCF = 42.15x (Enterprise Value 11.0b / FCF TTM 260.0m)
FCF Yield = 2.37% (FCF TTM 260.0m / Enterprise Value 11.0b)
FCF Margin = 8.15% (FCF TTM 260.0m / Revenue TTM 3.19b)
Net Margin = 13.45% (Net Income TTM 428.8m / Revenue TTM 3.19b)
Gross Margin = 71.88% ((Revenue TTM 3.19b - Cost of Revenue TTM 896.8m) / Revenue TTM)
Gross Margin QoQ = 75.07% (prev 70.18%)
Tobins Q-Ratio = 3.21 (Enterprise Value 11.0b / Total Assets 3.42b)
Interest Expense / Debt = 6.20% (Interest Expense 59.9m / Debt 966.7m)
Taxrate = 21.89% (120.2m / 549.1m)
NOPAT = 478.9m (EBIT 613.1m * (1 - 21.89%))
Current Ratio = 2.51 (Total Current Assets 2.04b / Total Current Liabilities 814.4m)
Debt / Equity = 0.61 (Debt 966.7m / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 0.53 (Net Debt 382.3m / EBITDA 718.6m)
Debt / FCF = 1.47 (Net Debt 382.3m / FCF TTM 260.0m)
Total Stockholder Equity = 1.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.31% (Net Income 428.8m / Total Assets 3.42b)
RoE = 29.48% (Net Income TTM 428.8m / Total Stockholder Equity 1.45b)
RoCE = 25.57% (EBIT 613.1m / Capital Employed (Equity 1.45b + L.T.Debt 943.0m))
RoIC = 19.46% (NOPAT 478.9m / Invested Capital 2.46b)
WACC = 6.17% (E(10.6b)/V(11.5b) * Re(6.29%) + D(966.7m)/V(11.5b) * Rd(6.20%) * (1-Tc(0.22)))
Discount Rate = 6.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.26 | Cagr: -2.64%
[DCF] Terminal Value 73.10% ; FCFF base≈324.5m ; Y1≈284.5m ; Y5≈229.9m
[DCF] Fair Price = 47.68 (EV 3.69b - Net Debt 382.3m = Equity 3.31b / Shares 69.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 97.71 | EPS CAGR: 34.49% | SUE: 4.0 | # QB: 3
Revenue Correlation: 99.81 | Revenue CAGR: 26.97% | SUE: 1.18 | # QB: 13
EPS current Quarter (2027-03-31): EPS=1.66 | Chg30d=+1.85% | Revisions=+7% | Analysts=18
EPS current Year (2026-12-31): EPS=6.77 | Chg30d=+4.11% | Revisions=+75% | GrowthEPS=+36.3% | GrowthRev=+22.0%
EPS next Year (2027-12-31): EPS=7.91 | Chg30d=+2.37% | Revisions=+32% | GrowthEPS=+16.8% | GrowthRev=+11.7%
[Analyst] Revisions Ratio: +47% (up=33, down=11)